April 9, 2024
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
April 8, 2024
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
April 4, 2024
Revolution Medicines to Participate in Upcoming Investor Conferences
March 28, 2024
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
February 26, 2024
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
February 20, 2024
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
February 1, 2024
Revolution Medicines to Participate in Upcoming Investor Conferences
January 4, 2024
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
November 9, 2023
Revolution Medicines Completes Acquisition of EQRx
November 8, 2023
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition